electroCore Earnings Call Transcripts
Fiscal Year 2026
-
The company highlighted strong revenue growth, expanding product lines for chronic pain, and strategic partnerships with the VA and Kaiser Permanente. Key differentiators include proprietary cervical vagus nerve stimulation technology and a focus on operational efficiency and new market opportunities.
-
Record quarterly revenue of $9.6M (up 43% YoY) with 87% gross margin and improved adjusted EBITDA loss. VA and consumer channels drove growth, and 2026 guidance for 30% revenue growth was reaffirmed. Leadership transition completed and new COO in place.
Fiscal Year 2025
-
Record 2025 revenue growth was driven by VA and wellness channels, with strong Truvaga sales and improved gross margin. Leadership transition is underway, and 2026 revenue is expected to grow ~30%, with new product launches and expanded federal and managed care focus.
-
Q3 2025 revenue rose 33% year-over-year to $8.7M, driven by VA channel growth and the Quell Fibromyalgia acquisition. Gross margin improved to 86%, and full-year guidance was raised. Profitability is delayed to fund expansion, with positive adjusted EBITDA expected in H2 2026.
-
Record Q2 revenue of $7.4M (up 20% YoY) driven by VA and wellness growth, with gross margin at 87%. Strategic investments are accelerating, delaying profitability but targeting $11.5–$12M in quarterly revenue for cash flow positivity.
-
Q1 2025 revenue rose 23% year-over-year to $6.7 million, with strong growth in both prescription and wellness channels. The acquisition of Neurometrics and new product launches are expected to drive further expansion, while gross margins remain robust at 85%.
-
Revenue growth remains strong with expanding insurance coverage and a diversified product portfolio. New clinical indications, recent acquisitions, and direct-to-consumer initiatives are expected to drive further growth and approach cash flow positivity.
-
Non-invasive neuromodulation products for headache, wellness, and military use drove $25M in 2024 revenue, with strong gross margins and expanding coverage. New acquisitions and clinical trials target PTSD, fibromyalgia, and substance abuse, supporting growth into 2026.
Fiscal Year 2024
-
2024 revenue grew 57% to $25.2M, driven by strong VA and Truvaga sales, with gross margin at 85% and net loss narrowing by 37%. Key developments include the NeuroMetrix acquisition, Spark Biomedical partnership, and expanded DTC channels.
-
Q3 2024 revenue rose 45% year-over-year to $6.6 million, with gross margin steady at 84% and net loss narrowing by 38%. VA channel and Truvaga sales drove growth, while TAC-STIM revenue was variable. Progress continues toward profitability and positive cash flow.
-
Strong revenue growth, high gross margins, and a diversified product portfolio drive expansion in prescription, wellness, and military markets. Pipeline advances in PTSD and substance abuse, with robust patent protection and plans for broader insurance coverage in 2025-2026.
-
Q2 2024 saw record revenue of $6.1M (up 73% YoY), 86% gross margin, and a 46% reduction in net loss. VA channel sales surged 120%, Truvaga and TAC-STIM product lines expanded, and $9M was raised, mostly from insiders. Positive cash flow is targeted for early 2025.